Tildrakizumab for moderate-to-severe plaque psoriasis in Chinese patients: A 12-week randomized placebo-controlled phase III trial with long-term extension

Yu Chen, Songmei Geng, Bin Yang, Yunhua Deng, Fuqiu Li, Xiaojing Kang, Mingye Bi, Furen Zhang, Yi Zhao, Weili Pan, Zhongwei Tian, Jinhua Xu, Zhenghua Zhang, Nan Yu, Xinsuo Duan, Shuping Guo, Qing Sun, James Weiquan Li, Juan Tao, Zhijun Liu, Yuanyuan Yin, Gang WangChinese 2024 · DOI

Abstract

ClinicalTrials.gov , NCT05108766.
BibTeX
@inproceedings{chen2024tildrakizumab,
  author = {Yu Chen and Songmei Geng and Bin Yang and Yunhua Deng and Fuqiu Li and Xiaojing Kang and Mingye Bi and Furen Zhang and Yi Zhao and Weili Pan and Zhongwei Tian and Jinhua Xu and Zhenghua Zhang and Nan Yu and Xinsuo Duan and Shuping Guo and Qing Sun and James Weiquan Li and Juan Tao and Zhijun Liu and Yuanyuan Yin and Gang Wang},
  title = {{Tildrakizumab for moderate-to-severe plaque psoriasis in Chinese patients: A 12-week randomized placebo-controlled phase III trial with long-term extension}},
  booktitle = {Chinese},
  year = {2024},
  doi = {10.1097/cm9.0000000000002873},
}

Loading related content...

Figure